Filing Flows › Karyopharm Therapeutics (KPTI) › Q2 2026
Karyopharm Therapeutics (KPTI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Karyopharm Therapeutics (KPTI) reported revenue of $33.4M for the second quarter 2026 (Q2 2026), -12% from a year earlier and -5% from the quarter before. Operating margin was -67.4%, net loss $67.0M (200.5% of revenue).
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.4M | -5% | -12% |
| Operating profit | −$22.5M | — | — |
| Net earnings | −$67.0M | — | — |
| Operating cash flow | −$24.9M | — | — |
What changed
Revenue was $33.4M in Q2 2026, down 12% year over year and down 5% from the previous quarter. Product was the largest line at 92% of revenue. License and Other lost $5.6M year over year (down 68%), 124% of the total change.
Operating costs exceeded revenue by $22.5M, an operating margin of -67.4%. Total costs fell 10% while revenue fell 12%. The quarter ended with a net loss of $67.0M, wider than the previous quarter's $22.4M loss. Net interest and other expense of $44.5M was the main reason.
Operating cash flow was −$24.9M. Non-cash charges added back $1.9M of share-based compensation. Working capital and other items added $40.2M.
Questions
What was Karyopharm Therapeutics' revenue in the second quarter 2026?
Karyopharm Therapeutics (KPTI) reported revenue of $33.4M for the second quarter 2026 (Q2 2026), -12% from a year earlier and -5% from the quarter before.
Was Karyopharm Therapeutics profitable in the second quarter 2026?
Operating loss was $22.5M (-67.4% of revenue) and net loss $67.0M.